Food allergy affects over 3 million Canadians, including almost 600,000 children. Researchers are committed to better understanding how to prevent, diagnose, treat, and eventually, cure this medical condition. Learn how you can participate in research studies.
Research study: Call for participation for children with tree nut allergy
A research study is underway in Hamilton, Ontario. The researchers are seeking children aged 1-16 years who have been diagnosed with tree nut allergy, specifically to cashew, pistachio, walnut, pecan, almond, or hazelnut.
The study is testing different immunotherapies to desensitize a person with tree nut allergy by repeated exposures to very small amounts of tree nut through sublingual immunotherapy (SLIT) or low-dose oral immunotherapy (IdOIT). SLIT is when a food allergen is placed under the tongue and OIT is when a food allergen is eaten.
Food Allergy Canada is involved in this research through a patient/caregiver partnership where we provide input on the design of the research, review research outcomes, and ensure the patient perspective is considered.
Please share with others whose children have tree nut allergy.
From the research team:
Now enrolling: TRADE study for children with tree nut allergy
Does your child have tree nut allergy and hopes to reduce their reactions to tree nuts? Your child may be eligible for our study to trial treatments for tree nut allergy. TRADE is a randomized trial which uses sublingual immunotherapy (SLIT) or low-dose oral immunotherapy (ldOIT) compared with a placebo to assess the ability of different immunotherapies to desensitize tree nut allergy.
- Children between 1-16 years old
- Diagnosed with tree nut allergy, specifically cashew, pistachio, walnut, pecan, almond, or hazelnut
- Skin prick test of 3mm or greater or a serum tree nut-specific IgE of greater than 0.35kUA/L
- Other eligibility criteria will apply
Participation in the study involves:
- Taking the study treatment for 52 weeks
- At least 10 study visits to the clinic, which is located in McMaster Children’s Hospital, 1200 Main Street West, Hamilton, ON
Potential benefits of this study include:
- Decreasing the participant’s reactivity to tree nuts after accidental ingestion and altering the natural progression of tree nut allergy by modifying the underlying immune response
- The participant may become clinically and immunologically tolerant to the tree nut
- Addressing unmet needs to establish safe tree nut allergy immunotherapy protocols and helping doctors and scientists to better understand food allergy
TRADE is led by Dr. Derek Chu MD PhD FRCPC at McMaster University Hamilton, Ontario and funded by the Canadian Institutes of Health Research, Ontario Ministry of Health and Long-Term Care, Ontario Medical Association, and Hamilton Health Sciences.
Research study – Call for participants: Children with peanut allergy
A research study is underway across North America. They are seeking children aged 4-7 years who have been diagnosed with peanut allergy and are currently following a strict peanut-free diet.
The study is testing an investigational drug patch to learn how well it works and how safe it is in children with peanut allergy. The purpose of the patch is to potentially desensitize a person with peanut allergy by repeated exposures to very small amounts of peanut via the skin.
Please share with others whose children have peanut allergy.
From the research team:
Now Enrolling: The VITESSE Phase 3 Study for Peanut Allergy
The VITESSE phase 3 clinical research study is looking for children 4 to 7 years of age who have been diagnosed with peanut allergy and are currently following a strict peanut-free diet. Study doctors are testing an investigational drug patch (also called study drug patch) to learn how well it works and how safe it is in children with peanut allergy.
What should I know about the VITESSE study?
- To be eligible for this study, participants must be*:
- 4 to 7 years of age
- Diagnosed with peanut allergy
- Currently following a strict peanut-free diet
*Other inclusion/exclusion criteria will apply.
- This study will consist of at least 12 study visits and 5 phone calls over a period of approximately 58 weeks (about 1 year)
- Participants will be randomly assigned (by chance) to receive the study drug patch or placebo patch (looks like the study drug but contains no active drug). Participants will have about a 67% (2 in 3) chance of receiving the study drug patch and about a 33% (1 in 3) chance of receiving the placebo patch
- The health and safety of participants will be monitored throughout the study
- Participant data and information will be kept confidential according to applicable laws for clinical research studies
- Study participants will receive all study-related procedures and the study drug patch or placebo patch at no cost
Study sponsored by DBV Technologies.